|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2003-6-12
|
|
pubmed:abstractText |
Azidothymidine (AZT, zidovudine) has been shown to reverse cisplatin resistance in cell culture. This phase I study was performed to determine the maximally tolerated dose (MTD) and dose-limiting toxicities of AZT when administered by continuous intravenous infusion in combination with cisplatin (CDDP), and to evaluate the pharmacokinetics of AZT in this setting.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
pubmed-author:AkmanStevenS,
pubmed-author:CarrollMaryM,
pubmed-author:ChowWarrenW,
pubmed-author:DoroshowJames HJH,
pubmed-author:HamasakiVictorV,
pubmed-author:HarrisonJonathanJ,
pubmed-author:JOBJ CJC,
pubmed-author:LeongLucilleL,
pubmed-author:MargolinKimK,
pubmed-author:MorganRobert JRJJr,
pubmed-author:NewmanEdward MEM,
pubmed-author:NilandJoyceJ,
pubmed-author:RaschkoJamesJ,
pubmed-author:ScanlonKevinK,
pubmed-author:SomloGeorgeG,
pubmed-author:SowersLawrenceL,
pubmed-author:TetefMerryM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
459-64
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12695856-Adult,
pubmed-meshheading:12695856-Aged,
pubmed-meshheading:12695856-Antimetabolites, Antineoplastic,
pubmed-meshheading:12695856-Antineoplastic Agents,
pubmed-meshheading:12695856-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12695856-Cisplatin,
pubmed-meshheading:12695856-Drug Resistance, Neoplasm,
pubmed-meshheading:12695856-Female,
pubmed-meshheading:12695856-Humans,
pubmed-meshheading:12695856-Male,
pubmed-meshheading:12695856-Middle Aged,
pubmed-meshheading:12695856-Neoplasms,
pubmed-meshheading:12695856-Zidovudine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
|
|
pubmed:affiliation |
Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 E. Duarte Rd, Duarte, CA 91010, USA. rmorgan@coh.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
